The 6 most recent market catalysts affecting $NTLA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 9, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $25 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor has reiterated a 'Buy' rating on Intellia Therapeutics (NTLA) and maintained a $25 price target. This action signifies that the analy…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 85
Intellia Therapeutics Announces FDA Acceptance For Its Biologics License Application For Ionvo-Z; FDA Sets March 10, 2027, As PDUFA Date
Intellia Therapeutics (NTLA) announced a major regulatory milestone: the FDA has accepted its Biologics License Application (BLA) for Ionvo-Z and granted it Priority Review. This i…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 65
Evercore ISI Group Upgrades Intellia Therapeutics to Outperform, Raises Price Target to $24
Evercore ISI Group's upgrade of Intellia Therapeutics (NTLA) to Outperform, coupled with a significant price target increase from $16 to $24, indicates a more bullish outlook from …
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 92
Intellia Therapeutics Q2 EPS $(0.80) Misses $(0.79) Estimate, Sales $7.659M Miss $13.904M Estimate
Intellia Therapeutics (NTLA) announced Q2 results that fell short of analyst expectations on both the top and bottom lines. The company reported a loss of $(0.80) per share, slight…
Jul 16, 2026
Corporate Catalyst
Bearish
Impact 75
Intellia Therapeutics shares are trading lower after Wolfe Research downgraded the stock from Peer Perform to Underperform rating and announced a $9 price target.
The downgrade of Intellia Therapeutics by Wolfe Research from 'Peer Perform' to 'Underperform' with a significantly lower price target of $9 is a strong negative signal for the com…
Jul 16, 2026
Corporate Catalyst
Bearish
Impact 75
Wolfe Research Downgrades Intellia Therapeutics to Underperform, Announces $9 Price Target
Wolfe Research's downgrade of Intellia Therapeutics (NTLA) to Underperform with a $9 price target is a significant event for the company. Analyst downgrades from reputable firms li…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.